| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
Nicotinamide riboside, a form of pyridine nucleoside with a nicotinamide, is an orally bioactive precursor to NAD+ and a source of vitamin B3. It can increase NAD[+] levels and activate SIRT1 and SIRT3.
| ln Vitro |
The acetylation status of SOD2 and Ndufa9 is decreased by nicotinamide riboside (0.5 nM; 24 hours) [1]. In C2C12, Hepa1.6, and HEK293 cells, nicotinamide riboside increases intracellular and mitochondrial NAD+ content in a concentration-dependent manner within the concentration range of 1-1000 μM [1]. Nicotinamide riboside supports innate immunity against coronavirus (CoV), one of the causes of COVID-19, and improves NAD and antiviral poly(ADP-ribose) polymerase (PARP) function [3].
|
|---|---|
| ln Vivo |
Nicotinamide riboside (oral; 400 mg/kg/day; for 16 weeks) raises intracellular and plasma NAD+ content in a tissue-specific way when taken long-term [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HEK293T Cell Tested Concentrations: 0.5 nM Incubation Duration: 24 hrs (hours) Experimental Results: diminished acetylation status of Ndufa9 and SOD2. |
| Animal Protocol |
Animal/Disease Models: 10weeks old C57Bl/6J mice [1]
Doses: 400 mg/kg Route of Administration: oral; daily; continued for 16 weeks Experimental Results: Plasma and intracellular NAD+ levels increased in a tissue-specific manner. |
| References |
|
| Additional Infomation |
N-ribosylnicotinamide is a pyridine nucleoside consisting of nicotinamide with a beta-D-ribofuranosyl moiety at the 1-position. It has a role as a human metabolite, a Saccharomyces cerevisiae metabolite, a mouse metabolite and a geroprotector. It is a N-glycosylnicotinamide and a pyridine nucleoside.
Nicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis). Nicotinamide riboside is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Nicotinamide riboside has been reported in Drosophila melanogaster, Homo sapiens, and other organisms with data available. Nicotinamide Riboside is an orally available form of vitamin B3 and precursor of nicotinamide adenine dinucleotide (NAD+) with potential use in the treatment of chemotherapy induced peripheral neuropathy (CIPN). Upon oral administration, nicotinamide riboside (NR) is converted to nicotinamide mononucleotide by the NR kinases, nicotinamide riboside kinase 1 (NRK 1) and nicotinamide riboside kinase 2 (NRK 2), to which a second adenine is transferred by nicotinamide mononucleotide adenylyl transferase to generate NAD+. NAD+, an essential redox coenzyme, may offer protective effects against axonal injury from both mechanical and neurotoxic injury, and maintenance of NAD+ may be protective in mitochondrial disease. NR may help elevate and maintain NAD+ levels, which may ameliorate potential mechanisms implicated in the development of CIPN including mitochondrial dysfunction and peripheral nerve degeneration. Nicotinamide riboside is a metabolite found in or produced by Saccharomyces cerevisiae. |
| Molecular Formula |
C₁₁H₁₅N₂O₅
|
|---|---|
| Molecular Weight |
255.25
|
| Exact Mass |
255.097
|
| CAS # |
1341-23-7
|
| Related CAS # |
Nicotinamide riboside chloride;23111-00-4;Nicotinamide riboside tartrate;2415657-86-0;Nicotinamide riboside malate;2415659-01-5
|
| PubChem CID |
439924
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.201g/cm3
|
| Boiling Point |
353.7ºC at 760mmHg
|
| Flash Point |
181.9ºC
|
| Vapour Pressure |
3.05E-07mmHg at 25°C
|
| Index of Refraction |
1.549
|
| LogP |
-2.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
314
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
|
| InChi Key |
JLEBZPBDRKPWTD-TURQNECASA-O
|
| InChi Code |
InChI=1S/C11H14N2O5/c12-10(17)6-2-1-3-13(4-6)11-9(16)8(15)7(5-14)18-11/h1-4,7-9,11,14-16H,5H2,(H-,12,17)/p+1/t7-,8-,9-,11-/m1/s1
|
| Chemical Name |
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide
|
| Synonyms |
N-RibosylnicotinamideNicotinamide-beta-riboside Nicotinamide ribonucleoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9177 mL | 19.5886 mL | 39.1773 mL | |
| 5 mM | 0.7835 mL | 3.9177 mL | 7.8355 mL | |
| 10 mM | 0.3918 mL | 1.9589 mL | 3.9177 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
